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Objective: The purpose of the present study is to compare the 
effect of two, different strategies for early parenteral AA 
supplementation in the range of the standard dose of AA (>1.5 
g/kg/day), on the short- and long-term growth parameters and 
other metabolic state in VLBW infants. 
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Design: Retrospective cohort study 
Setting: Thirty eight-bed neonatal intensive care unit at     
Asan Medical Center, Korea. 
Patients:  We included 109 patients who admitted to NICU over 
a period of January 2008 to December 2009. 
Methods: A chart review was done in a total of 109 VLBW 
infants hospitalized in our NICU from 2008 to 2009 if they had 
no major congenital anomalies or renal failure. During the study 
period, unit policy on the parenteral AA supplementation did not 
change except for the starting AA doses at the first day of life ; 
1.5 g/kg/day (n=56, standard protein group, SP, in 2008) 
versus 3.0 g/kg/day (n=53, high protein group, HP, in 2009). 
The AA dose was advanced by 0.5 g/kg/day to a target 
maximum of 3.5 to 4.0 g/kg/day. Daily protein and non-protein 
energy intakes and chemical laboratory profiles were collected 
for the first 14 days of life. Outcome variables including 
mortality and neonatal morbidities during hospitalization and 
growth parameters at postnatal 14 days, 36 weeks’, 6 
months’, and 12 months of corrected age(CA) were also 
collected.  
Results: The baseline clinical characteristics between the 2 
groups were similar. The mean protein intake during the first 
14 days of life was greater in the HP group than SP group 
(2.9±0.4 vs. 2.6±0.4/kg/d; p<0.001). Mean non-protein 
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energy intake and amount of enteral protein intake did not differ 
between the 2 groups. There was no significant difference in 
the weight, length and head circumference at postnatal 14 day, 
36 weeks’, 6 months’ and 12 months of CA between the HP 
and the SP groups. Peak plasma glucose level during the first 3 
days of life was lower in the HP group than in the SP group 
(116.4±23.6 vs. 136.5±38.3 mg/dL, p=0.001), while mean 
serum blood urea nitrogen level was higher in HP group 
compared with SP group.  
Conclusions: Early provision of higher dose of AA was well-
tolerated without significant metabolic adverse effects. In the 
range of standard parenteral AA protocol, no dose-response 
relationship was observed between the AA doses and growth 
outcomes in VLBW infants.  
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Advancement of medical care has remarkably improved 
survival of preterm infants. Technological and pharmacological 
advances of the last 30 years, such as increased prenatal 
referral to tertiary centers, antenatal steroid administration for 
lung maturation, initiation of assisted ventilation at delivery, 
surfactant replacement therapy, new techniques of ventilation, 
and regionalization of perinatal care resulted in improvement of 
perinatal management1. As a result, a substantial increase in 
survival of infants born mainly at extremely low gestational 
ages (< 28 weeks) has occurred2. However, as increasing more 
immature preterm infants survive, challenges related to 
providing preterm infants, especially very low birth weight 
(VLBW) infants, weighing less than 1,500g of birth weights, 
with optimal nutrition for growth and development have become 
daunting. Despite advance in perinatal medicine and nutritional 
protocols, growth in preterm infants hospitalized in the neonatal 
intensive care unit (NICU) is slower than that of intrauterine 
growth for same gestation infants3-5. Extrauterine growth 
restriction (EUGR, <10th percentile for gestational age) is 
associated with an increased risk of poor neurodevelopmental 
outcomes6-9, and inappropriate postnatal nutrition is an 
important contributor to growth failure10,11. As stated recently 
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by the European Society for Pediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) committee, the goal for 
premature infants is obtaining a functional outcome comparable 
to infants born at term12. Thus, it is crucial to optimize neonatal 
nutrition in a way that unhampered brain growth and 
development is stimulated 13.  
 
1. Extrauterine Growth Restriction (EUGR) and 
nutrition 
Poor in-hospital growth is the most frequent morbidity in 
VLBW population. According to Lemons et al.14, EUGR was 
presented in 97% of the VLBW infant. EUGR occurred in 100% 
of infants born at 501 to 750 g, 98% of infants born at 751 to 
1000 g, 97% of infants born at 1001 to 1250 g, and 95% of 
infants born at 1251 to 1500 g. Although EUGR has been 
present for a long time, few studies have evaluated the efficacy 
and safety of multiple interventions to prevent or decrease 
EUGR rates at discharge in VLBW infants15. Growth is 
influenced by many factors, such as genetic background, 
hormones, nutrition, and environment(Fig 1)16, and inadequate 
nutrition has long been suspected to be major cause of the 
EUGR17.  
As mentioned above, the major problems of EUGR is an 
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association of developmental outcome with slow growth during 
neonatal period and are particularly important from a nutritional 
point of view18-21. Since growth and development of the central 
nervous system are particularly rapid during the third trimester 
of gestation, it seems reasonable to assume that the impact of 
inadequate nutrition during any part of this period is likely to 
detrimental. 
In a number of observational studies, a relationship between 
slow weight gain and low protein intake among premature 
infants has been documented11,22-26. And these reports show 
that protein intakes are considerably did not reach the 
requirements, though energy intakes were close or even above 
requirements. In 2009, Stephens et al.27 demonstrated that 
increased first-week protein and energy intakes are associated 
with higher mental development index(MDI) scores and lower 
likelihood of length growth restrictions at 18 months. These 
findings have provided the major impetus for the adoption of 
vastly improved parenteral nutrition regimens in the days 
immediately following birth. 
 
2. Effects of nutrition on metabolic health in 
prematurity 
 Recent investigations have shown the early origins of 
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metabolic syndrome to be associated with prematurity. Barker 
emphasized that differences in nutritional experiences during 
sensitive periods in early life, both before and after birth, can 
program a person’s future development, metabolism, and 
health28. Other studies  reported that children who were born 
prematurely had an isolated reduction in insulin sensitivity29, 
and that a high carbohydrate and lower protein neonatal diet 
could lead to greater weight gain and a greater reduction in 
insulin sensitivity in preterm infants30. One randomized 
controlled trials demonstrated a causal relation between 
nutrition in infancy and later outcomes, including cognitive 
function and cardiovascular risk factors31. Moreover, the 
evidence led to conclusion that early nutritional environment 
interacts with an individual’s genetic disposition to program 
metabolism and development. Meanwhile, they also reported 
that relative under-nutrition early in the life in children (13 to 
16 years of age) who were born prematurely may have 
beneficial effects on insulin resistance and cardiovascular 
disease (CVD) risk. However, malnutrition may be likely to 
develop neurological impairment or short stature as well as 
metabolic syndrome and CVD. These findings make clinicians to 
face a dilemma with respect to the nutrition of preterm infants. 
Therefore, preterm infants must be fed the right amount, at the 
right time and early aggressive nutrition should be initiated 
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after birth not only to supply essential amino acids and fatty 
acids, but also to prevent starvation response; nutrient 
requirements change with development and gestational age. 
 
3. Amino acids (AA) supplementation in VLBW 
infants 
During the immediate newborn period, sick infants, especially 
preterm infants, may not tolerate standard amounts of nutrients 
normally delivered to clinically stable infants and may not 
tolerate adequate energy intakes for optimal utilization of AA. 
The administration of glucose alone may result in 
hyperglycemia and cannot fully prevent tissue catabolism, and 
early administration of protein as amino acids may decrease the 
risk for hyperglycemia and promote nitrogen retention32. 
During the early days following the birth of preterm infants, 
parenteral nutrition (PN) must replace the role of the placenta 
by providing a continuous supply of nutrients and minerals in 
order to fulfill the nutritional needs of growing fetuses. 
Although providing doses of macronutrients similar to those of 
placental transfer can be achieved with currently used method 
of neonatal PN, the optimal dose of AA which are the major 
building blocks for the growth of preterm infants, have been the 
topic of studies regarding the nutritional management of the 
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very low birth weight (VLBW) infants. A linear relationship 
between AA intake and nitrogen retention in both fetuses and 
neonates was revealed and a minimum intake of 1.0 to 1.5 
g/kg/d of AA has been recommended as the “standard dose” 
of early AA in PN in order to prevent a negative nitrogen 
balance33. However, this level is far from the AA dose of fetal 
transfer that can approximate ideal protein accretion and fetal 
growth. At least in part, EUGR may be attributable to the gap 
between the “standard dose” of AA in PN and those of the 
“fetal dose” (3.5 to 4.0 g/kg/day) during the early days after 
birth.  
Analysis of data from studies published before 1986 showed 
that weight gain (g/day) increases with linearly with increasing 
protein intakes up to about 4.2 g/kg/day34,35. The authors 
estimated that AA requirements weighing > 1,200g to grow like 
the fetus was about 3.0 g/kg/day. This value is similar to values 
derived from observational studies. In the study by Olsen et 
al.23 a single gram per kilogram of a single gram per kilogram of 
additional protein was associated with an increment of weight 
gain of 4.1 g/kg/day and in the study by Ernst et al.24, each 
gram per kilogram of protein was associated with weight gain of 
6.5 g/day (equivalent to 4.3 g/kg/day if weight is assumed to be 
1.5 kg). A randomized controlled trial by Poindexter et al.36 
revealed that infants provided ≥ 3 g/kg/day of AA at ≤ 5 
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days life had significantly better growth outcome at 36 weeks’ 
corrected aged in extremely low birth weight(ELBW, < 1,000g 
of birth weight)infants without distinct adverse effects.  
Despite concerns regarding the negative influence of an 
excess level of some AAs and/or their metabolites on 
premature infants, the metabolic safety of the administration of 
the fetal dose of AA during the early neonatal period has been 
studied even in extremely low birth weight infants with limited 
metabolic and excretory capacity37. Based on the above 
evidences, Ehrenkanz38 established a recommendations and 
evidence quality on early nutritional practice including AA 
administration for VLBW infants (Table 1)39 according to the 
quality of the available evidence, as defined in a policy 
statement by the American Academy of Pediatrics39. However, 
there are still conflicts regarding whether early and higher 
doses of AA administration in VLBW infants can translate into 
better outcomes in terms of their growth40. There have been a 
few studies demonstrating the benefit of a higher AA 
supplement on neonatal growth41-43, however, little is known 
regarding the effect of the fetal dose of AA administration in 







Provision of parenteral amino acid (AA) at the first day of life 
is now a widely accepted nutritional practice in the management 
of very low birth weight (VLBW) infant. However, it is not 
determined whether early and higher AA supplementation can 
translate into the better growth outcomes. The purpose of the 
present study is to compare the effect of two different 
parenteral AA supplementation strategies (targeted dose of 1.5 
g/kg/day versus 3.0 g/kg/day at the first day of life) on the 
short- and long-term growth parameters in VLBW infants. 
Furthermore, we examined that higher AA administration would 
be associated with metabolic beneficial effects and/or other 
complications. It was hypothesized that infants who received 
high protein intakes in early days of life would have better 













1. Study Subjects 
All newborn infants who were born at Asan Medical Center 
between January 2008 and December 2009, and with birth 
weights < 1,500g and gestational ages between 24+0 weeks 
and 33+6 weeks and who survived and were discharged after 
36 weeks of corrected age(CA), were enrolled. Exclusion 
criteria included infants with major congenital anomalies or 
acute renal failure (serum creatinine ≥ 1.6 mg/dL) and in 
whom the AA supply was restricted during the early neonatal 
period so as to avoid a higher urea nitrogen level. 
 
2. Nutritional management 
From January to December 2008, parenteral AA was started 
at a rate of 1.5 g/kg/d for all VLBW infants from the first day of 
life (mostly within the first hour of life) (standard protein, SP, 
group). Meanwhile, beginning in January 2009, the unit policy 
regarding the AA dose on the first day of life, was changed to 
3.0 g/kg/d (high protein, HP, group). AA was administered as a 
standardized preparation in a premixed bag containing 10% 
dextrose with 2.2% and 4.4% AA concentration for the SP and 
HP groups, respectively. From the second day of life, the AA 
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dose was increased in the form of an individualized PN solution. 
The unit policy regarding the increasing rate (by 0.5-1.0 
g/kg/d) and the target amount (3.5-4.0 g/kg/d) of AA in VLBW 
infants, did not differ between the two groups(Table 2). Fluid 
intake was restricted to 70-80 mL/kg/day on the first day of 
life and thereafter it was generally increased by 10-20 
mL/kg/day, reaching 130-140 mL/kg day at 10-14 postnatal 
days by monitoring the body weight, serum sodium, and urine 
volume. Except for the AA doses, there were no differences in 
the other nutritional strategies for parenteral (dextrose, lipid 
and minerals) and enteral nutrition between the two periods; 
and dextrose was administered to maintain the serum blood 
glucose between 80 and 180 mg/dL in an effort to avoid 
hyperglycemia (serum glucose concentration > 200 mg/dL) 
when the hyperglycemia was managed with a decreasing 
glucose infusion rate and/or intravenous insulin. Intravenous 
lipid emulsion was initiated on the second day of life at a rate of 
0.5 g/kg/day and was increased by 0.5 to 1.0 g/kg/day to 
maintain a target of 3.0 g/kg/day. Enteral feeding was initiated 
as trophic feeding with breast milk or, if not available, with 
preterm formula once the infant was considered to be able to 
tolerate enteral feeding. As enteral feeding was advanced, the 
amount of intravenous fluid and, accordingly, the dose of AA 
decreased. When the infant fed with breast milk could tolerate 
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100 mL/kg/day of enteral feeding volume and was at least after 
two weeks old, human milk fortifier (HMF®, Maeil, Korea) was 
mixed with their mothers’ milk in the patients fed with breast 
milk. PN supplementation was stopped when feedings reached 
130 to 140 ml/kg/day. All patients were discharged fed with PM 
or fortified BM or both, but the detailed data regarding the 
post-discharge formula could not be investigated. 
 
3. Data collection and monitoring 
Data were collected using an electronic medical records 
system. Demographic parameters and perinatal data including 
the use of antenatal steroid, APGAR scores, and CRIB II scores, 
were obtained. Other outcomes of the neonatal mortality and 
morbidities which could affect their growth, were also obtained 
and included: respiratory distress syndrome, bronchopulmonary 
dysplasia (defined as oxygen requirement at the CA of 36 
weeks); indomethacin treatment of patent ductus arteriosus 
(PDA); PDA ligation; early- or late- onset sepsis (defined as 
identification of bacteria or fungus cultured in the blood or 
cerebrospinal fluid within or after seven days of life, 
respectively); severe-grade (Grade 3 or 4 by Papille 
classification) intraventricular hemorrhage; retinopathy of 
prematurity requiring laser therapy; necrotizing enterocolitis or 
intestinal perforation that required surgical and PN-associated 
１２ 
 
cholestasis (direct bilirubin > 2.0 mg/dL) and the days of 
oxygen supplement; mechanical ventilator therapy; and 
hospitalization. Detailed data regarding the nutritional 
management were collected from an electronic nutritional chart 
program developed by our unit. In this program, the daily 
amount and calories provided by each major nutrient were 
automatically calculated from the individualized PN and enteral 
feeding orders which were confirmed or modified by a neonatal 
pharmacist. Actually administered doses (g/kg/d) of AA and the 
total and non-protein calories (kcal) administered both 
parenterally and enterally, were calculated during the first 14 
days of life. In order to evaluate the tolerability and adverse 
effects of AA intake, the BUN, serum creatinine, bicarbonate, 
base deficit, blood sugar level, and potassium level were also 
obtained.  
During hospitalization, body weight was measured daily using 
digital scales accurate to 10 g. Height and head circumference 
were measured weekly and at 36 weeks of CA age using a fixed 
head board and movable foot board and with a non-stretchable 
tape at the maximal occipitofrontal circumference. Weight, 
height, and head circumferences were compared with the latest 
intrauterine reference values7 using z scores. As our unit has a 
routine clinic visit program for all VLBW infant survivors, the 
infants were followed at least every month until 6 months of CA 
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age and thereafter at least every two months till 12 months of 
CA. The growth profile was measured by calculating the z score 
change from birth to 36 weeks, 6 months, and 12 months of CA.  
 
4. Statistical analysis 
All analyses were performed using SPSS version 12 (SPSS, 
Inc, Chicago, IL, USA). Normally distributed data were 
presented as mean values with SD, and the patient groups were 
compared using a t-test. Non-normally distributed data are 
presented as the median value with a range and the groups 
were compared using the Mann-Whitney test. Categorial data 
are presented as actual numbers or percentages, and the 
groups were compared by the chi-square test. 
Univariate and stepwise multivariate analysis were used to 
evaluate the influence of the clinical characteristics and the AA 
intake of growth expressed as z-score changes from birth to 
each time when the growth data was assessed.    
The relationship between AA intake and serum BUN level was 
determined using Pearson’s correlation coefficient (r or r2). 







IV. Results  
 
After discharge, 9 infants died within 12 months (n=5 in the 
SP group vs. n=4 in the HP group), and 19 infants (n= 11 in 
the SP group vs. n = 8 in the HP group) were lost to follow-up. 
Finally, a total of 109 patients were included in the study 
analysis (Figure 2). 
Demographic and perinatal data did not differ in the two study 
groups (Table 3). The HP group received 11% more AA intake 
than the SP group for the first two weeks, and this was mostly 
due to the difference in the AA intake during the first week of 
life (Figure 3). The total amount of AA did not reach the target 
requirements (3.5-4.0 g/kg/d) till at the end of the initial 14 
days after birth, because of the slow advance in parenteral and 
enteral feeding volume than we planned. There were no 
differences in the fluid volume, non-protein intake or enteral 
intakes between the study groups. The proportion of infants fed 
with preterm formula or fortified BM also did not differ between 
the two study groups during hospitalization (Table 4). The 
mean and peak BUN levels during the first two weeks of life 
were higher in the HP group (Figure 4), although the incidence 
of BUN > 40 mg/dL did not differ between the two groups. The 
mean and peak serum potassium and glucose levels and the 
incidence of hyperkalemia and hyperglycemia also did not differ 
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between the two study groups (Table 5). However, during the 
first three days of life, the peak blood glucose level was 
significantly lower in the HP group than in the SP group (P = 
0.001). During the first three days of life, a linear regression 
analysis revealed a significant correlation between the AA 
intake and the mean glucose level, while adjusting for  
gestational age (r2=0.248, P=0.009)(Figure 5).  
There were no differences in the percentage of weight loss 
from birth weight and in the days required to regain birth 
weight between the SP and the HP groups. The proportion of 
the patients who regained their birth weight after two weeks of 
life also did not differ between the two study groups (Figure 6). 
There were no differences in the neonatal morbidities    
(Table 6). 
In terms of the z-score change from birth to postnatal 14 days 
and 36 weeks, 6 months and 12 months CA, the changes in all 
of the growth parameters did not differ between the two groups 
(Figure 7). Multivariate analysis revealed that the z-score of 
the weight, height, and head circumference changes from birth 
to CA 36 weeks, could be explained by gestational age, the z-
score at birth, duration of hospitalization, and the CRIB II score 
at birth. However, the mean AA intake during the first 14 days 
of life was not a determinant of any change in growth 
parameters at CA 36 weeks (Table 7). Likewise, the z-score 
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changes of the growth parameter from birth to 6 month and to 


























 In the present study, administration of a higher dose of AA in 
the VLBW infants, approximating the fetal AA transfer rate 
from the first day of life, did not result in better growth 
outcomes than in the group with the “standard dose” of AA.  
Protein and energy intake meeting the recommended dietary 
intakes are rarely achieved in VLBW infants and they inevitably 
experience cumulative energy and protein deficits during the 
initial few postnatal weeks33,37. A dietary intake of protein of 
3.0 g/kg/day or more from the first day of life is thought to 
prevent the interruption or reduction of the fetal dose of AA 
transfer and, thereby, theoretically can minimize postnatal 
growth restriction. Although several studies have addressed the 
effect of early and “aggressive” nutrition on the growth 
outcomes, most are observational studies and the effect of 
parenteral AA was not independently investigated.36,40-43 Then, 
it is no wonder that most studies of nutritional interventions in 
preterm infants have been interested in the enteral feeding 
strategies rather than in early parenteral nutrition, with a 
different kind of enrichment protocol of AA and/or calories.8,44-
46. Only a multicenter, randomized trial comparing two groups 
with different dosing strategies of parenteral AA, demonstrated 
a result similar to ours, in which the higher starting dose and 
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the faster advancement in the AA supplementation did not lead 
to better growth outcome at 28 days of age in the premature 
infants of < 30 weeks of gestation40.   
On the other hand, an observational study by Maggio et al., 
with a very similar design of nutritional strategies, including the 
AA dose, to ours, reported better height and weight gain in the 
higher AA group at the time of their hospital discharge42. In that 
study, the mean AA intake during the first two weeks of life 
was independently associated with weight and height z-scores 
in the short-term.  
However, the intake of AA during the first two weeks of life 
did not correlate with the changes in the Z-scores of any of the 
growth parameters in our study.     
The reasons for this discrepancy are unclear. However, our 
enrolled study patients were more mature (approximately 30 
weeks vs. 27 weeks of gestational age) and the proportion of 
the small for gestational age (SGA) preterm infants was higher 
(30% versus 9%) than in Maggio’s study. The effect of early 
AA intervention can be attenuated in the more mature infant 
group with faster achieving target enteral feeding and in SGA 






 In our study, the metabolic benefit of higher AA 
supplementation was demonstrated in terms of serum glucose 
control, especially the peak blood glucose level was lower in 
the HP group during the first three days after birth(Table 4).  
Moreover, there was linear correlation of AA dose with mean 
serum glucose level during first three days of life(Figure 5), 
The increased concentration of the extracellular AA level, 
especially leucine, stimulates intracellular protein synthesis and 
suppresses protein breakdown, presumably by stimulating 
insulin secretion49. This insulin-dependent proteolysis 
suppression by AA has not been consistently documented in 
preterm infants previously50,51, thus, our study would be a 
useful reference of dose-response relationship between AA 
and serum glucose level. Otherwise, several comparative 
studies composed of groups with different AA doses, failed to 
demonstrate the greater risk of hyperkalemia with a range of 
clinical concern in the group with the lower AA intake 32,42,52. 
The metabolic benefit of early and higher AA infusion in a 
specific study group can be influenced by several factors such 
as the disease severity, patient maturity, and renal functions. 
As for the hyperkalemia, in particular, other factors such as 
exposure to antenatal corticosteroid treatment, can be relates 
to the early serum potassium levels53·54. However, these 




The clinical implication of a higher peak BUN level in our 
study’s HP group is not clear. Even in this group, the mean 
peak BUN level was within the cord blood BUN range55 and the 
proportion of patients with a peak BUN level over 40 mg/dL 
was also not greater than that seen in the SP group. No patients 
in either group demonstrated a serum BUN level > 60 mg/dL 
during the initial two weeks, and the advance in AA dose did not 
have to be stopped based solely on the serum AA levels. This 
may be due to the characteristics of the enrolled patients as 
those with acute renal failure had been excluded. Of course, 
there are still concerns regarding the potential risk of a high 
BUN and/or ammonia level in the developing brains of the 
extremely premature patient group52. However, until now, there 
has been no reliable evidence of a detrimental effect on the 
neurodevelopmental consequences caused by uremia of the 
degree commonly encountered during the early neonatal period 
in premature infants37 The difference in the mean BUN level 
between our study groups might have resulted from the 
difference in the AA doses, although other investigators have 
failed to correlate the serum BUN levels with the amount of AA 
intake within three56 or 15 days57 after birth in more premature 




There are some limitations to our retrospective study. First, 
as mentioned above, we did not reach the targeted total dose of 
AA because of the fluid volume restriction with other 
concomitant drugs’ continuous infusion (e.g., inotropes, 
sedatives). Thus, the difference of the amount of AA had 
diminished than we planned, and it would be the reason two 
groups did not show significant difference in growth rates than 
we expected. Second, the influences of unexpected changes in 
the patient care other than nutritional factors could not be 
completely controlled, especially during the first two weeks 
after birth. However, factors potentially affecting the early 
growth rate, such as early neonatal morbidities and fluid 
management protocol, did not differ between the two study 
groups. Moreover, nutritional practices other than the AA doses 
did not change and were controlled and monitored by the same 
pharmacist. Third, nutritional strategies during the 
hospitalization and afterward up to the last time point of growth 
parameter could not be strictly regulated. However, the type of 
feeding formula did not differ between the two groups, although 
detailed data could not be obtained. Finally, the nutritional 
benefit (or risk) for the HP group over the SP group could not 
be evaluated in terms of nutritional quality. Lean body mass in 
preterm infants is less well-developed and the proportions of 
fat deposition could be affected by several factors such as the 
２２ 
 
disease severity58. Comparison analysis of the lean body mass 


























In conclusion, changes in nutritional practice by increasing 
the starting dose of AA from 1.5 to 3.0 g/kg/day and earlier 
achievement of the fetal dose of AA transfer, did not result in a 
better growth outcome in the VLBW infants assessed in our 
study. Further, well-controlled, prospective studies will be 
needed to determine the effect of early and higher AA intake on 
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Figure 1. Interaction between early diet and genes in defining 
relevant health and quality of life outcome. CHO, indicates 







Figure 2. Flowchart of study population 
 
 
137 infants without 
     congenital anomalies and renal failure  
 
Admissions Excluded  
(n=28) 
 
Lost to follow up until CA 12 months (n=19) 









SP outcomes         HP outcomes  







Figure 3. Mean ± SD value of the daily amino acid doses in 
patients managed with the standard protein (SP) and the high 














Figure 4. A comparison of mean blood urea nitrogen(BUN) level 
for two groups 
 
 
Box and whiskers plot of maximum glucose level; Bars represent 





















Figure 5. Correlation of mean amino acid dose with mean serum 







































Figure 6. Body weight changes within two weeks of life 
 
 
Continuous variables are presented as Mean + SD; Wt, indicates 
Weight; PNA, indicates postnatal age. Differences of all variables 












Figure 7. Z score change of growth parameters from birth to 
postnatal 14 days and 36 weeks, 6 months, and 12 months of 
corrected age: (A) weight, (B) height, and (C) Head 



















Table 1. Evidence-Based Early Nutritional Practice for VLBW 
Infants: Recommendations and Evidence Quality  
(Data are from reference 38)  
 
*Strength of Recommendation: strongly recommended; recommended; option; 
not recommended. 
†Grade of Evidence Quality: A, Well-designed, RCTs performed on 
appropriate populations; B, RCTs with minor limitations, overwhelmingly 
consistent evidence from observational studies; C, Observational studies 
(case-control and cohort design); D, Expert opinion (case reports, 






Prompt provision of energy:  
Glucose infusion providing about 6 mg/kg/min 
Increase to about 10 mg/kg/d by 7 days of age 
Maintain blood sugar 50 -120 mg/dL 
Recommended B 
Prompt provision of parenteral amino acids: 
Initiate 3.0 g/kg/d within hours of birth 
Advance to 4.0 g/kg/d by 0.5-1.0 g/kg/d steps 
Recommended B 
Initiate lipid emulsion within the first 24-30 hrs  
of birth:  
Start 0.5 to 1.0 g/kg/d 
Advance to 3.0-3.5 g/kg/d by 0.5-1.0 g/kg/d  
steps 
Recommended B 
Initiate trophic feedings by 5 days of age  
Provide about 10 mL/kg/ 
Begin advancing to 150 mL/kg/d by 10-20 




Table 2. Parenteral nutrition dosing strategies within          
14 days of life 






Starting dose 1.5 Starting dose 3.0 
Advancement: 0.5-1.0 
Goal : 3.5-4.0 
Dextrose  
(mg/kg/min) 
Initiation : 4-8 




Initiation : 0.5-1 
Advancement : 0.5-1 
Goal : 3 
Isocaloric 
(kcal/kg/day) 













Table 3. Demographic & Clinical characteristics of the study 
population 
 SP (N=56) HP (N=53) P value 
Gestational age(weeks) a 30.3 ± 2.3 30.1 ± 2.6 0.603 
Birth weight (g) 1192 ± 232 1163 ± 240 0.520 
Birth length (cm) 37.6 ± 2.7 37.9 ± 3.2 0.580 
Birth HC(cm) 27.0 ± 2.0 26.6 ± 1.8 0.317 
SGA, n(%) 19 (33.9) 14 (26.4) 0.413 
Gender, Male : Female 29:27 23:30 0.391 
Antenatal steroids, n(%) 
Apgar score 1minute 
Apgar score 5 minutes 
CRIB II scores 
Surfactant therapy, n(%) 
42 (75.0) 
5.6 ± 1.8 
7.6 ± 1.1 
6.4 ± 2.6 
9 (16.1) 
34 (64.2) 
5.4 ± 2.0 
7.5 ± 1.5 







a Data are presented as number (%) and mean ± SD unless otherwise 
specified. 
HC, indicated Head Circumference; SGA, indicates Small for 









Table 4. Nutritional intake during the initial 14 days of life 
  SP (N=56) HP (N=53) P value 
Parenteral nutrition (day) a 32.2 ± 18.3 30.8 ± 20.3 0.925 
Age at start enteral feeding (day) 3.4 ± 3.9 4.1 ± 5.6 0.790 
Age at 130mL/kg (day) 11.1 ± 6.7 12.9±10.1 0.259 
Fluid intake (mL/kg/d) 105.3 ± 12.6 104.6 ± 12.6 0.758 
Enteral intake (mL/kg/d) 25.6 ± 23.6 26.8 ± 24.3 0.498 
Total protein intake (g/kg/d) 2.6 ± 0.4 2.9 ± 0.4 <0.001 
IV protein intake(g/kg/d) 2.2 ± 0.6 2.4 ± 0.5 0.010 
Enteral protein intake (g/kg/d) 0.5 ± 0.5 0.5 ± 0.5 0.847 
Nonprotein calories (kcal/kg/d) 72.5 ± 13.2 73.6 ± 10.9 0.618 
BM+PM : PM : BM (n) b 43 : 10 : 3 38 : 13 : 2 0.549 
a Data are presented as number (%) and mean ± SD unless otherwise 
specified. 














Table 5. Nutrition-associated laboratory values during the initial 
14 days of life 
a Data are presented as number (%) and mean ± SD unless otherwise 
specified. 
BUN, indicates blood urea nitrogen; BST, indicates blood sugar test; 










 SP (N=56) HP (N=53) P value 
BUN (mg/dL) 
a
 14.8 ± 6.7 19.2 ± 7.0 0.005 
Peak BUN > 40 mg/dL, n (%) 5 (8.9) 9 (17.0) 0.259 
Serum creatinine (mg/dL) 0.81 ± 0.19 0.79 ± 0.17 0.568 
Bicarbonate (mEq/dL) 22.8 ± 2.3 22.4 ± 2.4 0.349 
Base deficit -2.9 ± 1.7 -3.6 ± 2.4 0.077 
Serum glucose (mg/dL) 103.1 ± 23.3 105.7 ± 24.9 0.565 
Serum glucose > 200mg/dL, 
n (%) 
7 (12.5) 6 (11.5) 1.000 




Table 6. Neonatal morbidities between the HP and the SP groups 
at discharge 
 SP (N=56) HP (N=53) P value 
Oxygen therapy (day) 
a
 12.3 ± 22.5 18.9 ± 27.1 0.167 
Mechanical ventilation (day) 5.8 ± 11.7 9.5 ± 14.7 0.141 
CA at discharge (week) 38.2 ± 2.4 37.6 ± 1.8 0.457 
Length of stay (day) 
BPD, n (%) 
b 
54.9 ± 20.6 
11 (19.6) 




PDA, n (%) 22 (39.3) 27 (50.9) 0.251 
PDA – surgery, n (%) 2 (3.6) 4 (7.5) 0.429 
Early onset sepsis, n (%) 2 (3.6) 0 (0) 0.496 
Late onset sepsis, n (%) 8 (14.3) 16 (30.2) 0.064 
IVH ≥ grade 3, n(%) 1 (1.8) 0 (0) 1.000 
ROP - surgery, n (%) 1 (1.8) 5 (9.4) 0.107 
NEC/SIP, n (%) 0 (0) 0 (0) - 
Direct bilirubin > 2 mg/dL,     
n (%) 
3 (5.4) 5 (9.4) 0.481 
a Data are presented as number (%) and mean ± SD unless otherwise 
specified. 
CA, indicates corrected age; BPD, indicates bronchopulmonary 
dysplasia; PDA, indicates patent ductus arteriosus; IVH, indicates 
intraventricular hemorrhage; ROP, indicates retinopathy of 
prematurity; NEC, indicates necrotizing enterocolitis; SIP, indicates 
spontaneous intestinal perforation. 
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Table 7. Multiple regression: adjusted independent variables determining z score between birth and 36 weeks of 
corrected age (CA) 
 Δ z score weight Δ z score length Δ z score HC 
Gestational agea -0.134 ± 0.050** -0.175 ± 0.053** -0.240 ± 0.054** 
z score at birth -0.466 ± 0.056** -0.567 ± 0.061** -0.708 ± 0.069** 
CRIB II score -0.045 ± 0.028 -0.071 ± 0.035* -0.016 ± 0.162 
Protein intake during 14d 0.038 ± 0.116 0.113 ± 0.154 0.025 ± 0.162 
Hospitalization days  -0.018 ± 0.003** -0.014 ± 0.005** -0.020 ± 0.005** 
Mean NPC during 14d -0.001 ± 0.004 0.004 ± 0.006 0.006 ± 0.006 
Goodness of fit (r2) 0.691 0.575 0.633 
aData are presented as mean ± SD; HC, indicates head circumference; CRIB, indicates Clinical Risk Index for Babies; NPC, 
indicates nonprotein calorie. 
* P < 0.01  







출생체  1.5kg 미만  극소  체  
미 아에  생후 첫 2주 간 아미노산 
공 량에 른 장  사상태  
 
울 학  보건 학원 
보건학과 보건통계학 공 
양 사 미 
 
연구목 : 출생체  1.5 kg 미만  극소 체  미 아는 장 
이 구조 , 능  미 하여 맥 양에 한 존도가 
높다. 특히, 자궁 내 태아가 모체 부  다량  공 는 
아미노산  체내 단  합   요한 열량 공 원  사용  뿐 
아니라, 생후  고 당증  지하는 데 효과가 있다고 알  
있어 미 아  상  장  달  해 는 출생 에 
한 양  아미노산 여가 필 이다. 이에 본 연구에 는 
출생체  1.5kg 미만인 극소 체  미 아에  출생  단 질 
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여 용량 차이가 단 간, 장 간 장  사상태에 미 는 
향  분 하고자 한다.  
 
연구 상  법: 2008  1 월부  2009  12 월 지 
울아산병원 신생아 자실에 입원한 출생체  1.5kg 미만  
극소 체  미 아를 상  자  조사를 통한 후향  
연구 분  하 다. 2008 에 출생한 자군 ( 단 여군, 
SP)  생후 첫 날 단 공  목 량  1.5g/kg/d  시작하여 하루 
0.5g/kg/d 씩 증량해 종 여량  3.5-4g/kg/d 에 이르도  
하 고, 2009  이후 출생한 미 아(고용량단 여군, HP)는 
생후 첫 날 공  목 량  2  증가시킨 3.0g/kg/d  시작하며, 
SP 군과 동일하게 하루 0.5g/kg/d 씩 증량하여 종 공 량이 3.5-
4g/kg/d 가 도  하 다.  그룹 간 장 를 해 생후 체  
변 , 출생체  회복 간, 장 변 량, 출생 시 신체계  z 
score  생후 14 일 째, 연 36 주, 생후 6 개월  12 개월 
째 신체계  z score 차이를 분  하 다. 또한 BUN,  
탄산농도, 당, 칼륨  등 아미노산 여량과  
액학  , 장 달에 향    있는 양  요인  
합병증  조사하 다. 
연구결과: 109 명  자를 상  분 한 결과, 생후 14 일 간 
아미노산  HP 군이 SP 군보다 11% 도 많  양이 
여 었다(2.9±0.4 vs 2.6±0.4 g/kg/d, p<0.001). 생후 첫 3 일 
간 고 장포도당 (peak plasma glucose level)는 HP 군이 
SP 군 보다 하게 낮았 며(116±24 vs. 137±39 mg/Dl, 
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p<0.01), 14 일 간 평균 BUN(blood urea nitrogen) 는 HP 
그룹이 SP 그룹보다 높게 었다(19.2±7.0 vs 14.8±6.7 mg/dL, 
p<0.01). 출생 부  생후 14 일째, 연  36 주, 6 개월, 
12 개월 째 z score  변 량   군 간에 한 차이가 
없었 며, 다변량 회귀분 에 는 재태연 , 출생 시 신체계 z 
score, 재원 간(p<0.05)이 출생 부  연  36 주 지  z 
score 변 량과 통계  한 변  어 미 아  
장에 독립  인자  미가 있었  면, 아미노산 여량과 
장속도 간에는 한 상  보이지 않았다. 
 
결 : 생후 14일 간 극소 체  미 아에게 여하는 고 용량 
아미노산   용량에 하여 특별한 사  부작용 없이 출생 
 고 당증 도를 감소시키는 데 한 변  작용하 다. 
그러나 극소 미 아에  출생  아미노산 여량과 출생 후 
1  간 장 달 간에는 뚜 한 양-  계를 보이지 않았다. 
향후 향  연구를 통해 미 아  생후  고 용량 아미노산 
여에 른 장  장 평가  용-효  분 이 필요할 
것  생각 다. 
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